Late-life depression with cognitive control impairment
Conditions
Interventions
Elderly depression patients with cognitive control impairment:Escitalopram tablets (10mg-20mg/ day, centralized procurement, Shandong Jingwei Pharmaceutical Co., LTD.) or sertraline hydrochloride tabl
Sponsors
Beijing An Ding Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
60 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 60-75 years, Han Chinese, right-handed, both genders. 2. Meet the diagnostic criteria for depressive disorder according to DSM-5. 3. First episode, never received systematic antidepressant treatment, disease duration within 2 years. 4. HAMD-17 >=17 points (moderate depression or above). 5. At least one of the Trail Making Test (TMT-A and TMT-B) completion times is more than one standard deviation or more above the normal control (compared with the completion times of normal elderly controls previously recruited by our research group). 6. Mini-Mental State Examination (MMSE) >20 points for primary school education, and MMSE >24 points for others. 7. Education level of primary school or above, able to understand the scale or test content. 8. Obtain written informed consent from the subject and their family.
Exclusion criteria
Exclusion criteria: 1. Visual or auditory abnormalities. 2. Significant suicide risk (item 3 score of HAMD-17 >=3). 3. Subjects meeting DSM-5 diagnostic criteria for other mental disorders, such as schizophrenia spectrum and other psychotic disorders, bipolar disorder, anxiety disorders, obsessive-compulsive and related disorders, trauma- and stressor-related disorders, dissociative disorders, etc. 4. History of cranial disease, brain injury, epilepsy, or other neurological diseases. 5. History of severe systemic diseases involving the cardiovascular, respiratory, or immune systems. 6. History of substance abuse, active suicidal attempts, or electroconvulsive therapy. 7. Presence of metal implants such as dentures, aneurysm clips, pacemakers, or metal fixators. 8. Taking lorazepam >2 mg/day (or equivalent benzodiazepines). 9. Pregnant, breastfeeding, or planning to become pregnant.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall cognitive function;Depressive symptoms;Executive function;Brain connection;Model performance; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse event; | — |
Countries
China
Contacts
Public ContactLiu Chaomeng
Beijing An Ding Hospital, Capital Medical University
Outcome results
None listed